• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

1,141
109
76
71
69

COUNTRY

70
22
16
10
9

CATEGORIES

  • 574
  • 121
  • 550
  • 75
  • 526
  • 43
  • 505
  • 18
  • 18
  • 23

PRICE

1,036
1,236
1,970
2,999

PUBLISHED

26
210
659
2,999

PRODUCT TYPE

2,426
494
69
7
1
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
Neuroendocrine Tumors Drug Pipeline Update 2014 Neuroendocrine Tumors Drug Pipeline Update 2014 - Product Thumbnail Image

Neuroendocrine Tumors Drug Pipeline Update 2014

There are today 78 companies plus partners developing 86 neuroendocrine tumor drugs in 125 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount...

July 2014
FROM
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2014 Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2014

Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. However, these three successful drugs are just...

July 2014
FROM
Cytokine Therapy in Oncology Drug Pipeline Update 2014 Cytokine Therapy in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Cytokine Therapy in Oncology Drug Pipeline Update 2014

There are today 81 companies plus partners developing 105 cytokine drugs in 217 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs...

July 2014
FROM
Cellular Therapy in Oncology Drug Pipeline Update 2014 Cellular Therapy in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Cellular Therapy in Oncology Drug Pipeline Update 2014

There are today 84 companies plus partners developing 96 cellular therapy drugs in 191 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased...

July 2014
FROM
Angiogenesis in Oncology Drug Pipeline Update 2014 Angiogenesis in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Angiogenesis in Oncology Drug Pipeline Update 2014

There are today 305 companies plus partners developing 376 angiogenesis drugs in 1674 developmental projects in cancer. In addition, there are 9 suspended drugs and the accumulated number of ceased...

July 2014
FROM
Biologicals in Oncology Drug Pipeline Update 2014 Biologicals in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Biologicals in Oncology Drug Pipeline Update 2014

This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies. There are today 908 companies plus partners developing 1686...

July 2014
FROM
Hematological Cancers Drug Pipeline Update 2014 Hematological Cancers Drug Pipeline Update 2014 - Product Thumbnail Image

Hematological Cancers Drug Pipeline Update 2014

Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity. There are today 439 companies plus partners developing...

July 2014
FROM
Bladder Cancer Drug Pipeline Update 2014 Bladder Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Bladder Cancer Drug Pipeline Update 2014

According to the American Cancer Society, bladder cancer is the 6th most common cancer in the U.S. Bladder cancer occurs among both men and women. When found and treated early, the 5 year survival rate...

July 2014
FROM
Nucleic Acid Therapies in Oncology Drug Pipeline Update 2014 Nucleic Acid Therapies in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Nucleic Acid Therapies in Oncology Drug Pipeline Update 2014

Nucleic acid therapies in oncology includes: Gene Therapy, DNA vaccine, Other DNA technologies, RNA Interference (RNAi), Small interfering RNA (siRNA), Antisense RNA and Ribozymes. There are today 229...

July 2014
FROM
Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update 2014 Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update 2014

Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the...

July 2014
FROM
Targeting Cell Adhesion Molecules (CAMs) for the Treatment of Cancer Drug Pipeline Update 2014 Targeting Cell Adhesion Molecules (CAMs) for the Treatment of Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Targeting Cell Adhesion Molecules (CAMs) for the Treatment of Cancer Drug Pipeline Update 2014

Cell adhesion molecules are (glyco)proteins expressed on the cell surface and play a critical role in a wide array of biologic processes that include hemostasis, the immune response, inflammation, embryogenesis,...

July 2014
FROM
Antibodies in Oncology Drug Pipeline Update 2014 Antibodies in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Antibodies in Oncology Drug Pipeline Update 2014

The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the...

July 2014
FROM
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2014 Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2014

Aberrant activation of the Hedgehog pathway has been associated with a number of human malignancies including carcinoma of lung, esophagus, pancreas and prostate. There are today 119 companies plus...

July 2014
FROM
Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014 Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014

Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified...

July 2014
FROM
Pancreatic Cancer Drug Pathway Analyzer 2014 Pancreatic Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Pancreatic Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 294 targeted molecular therapies known to affect more than 246 specific intracellular signaling pathways...

July 2014
FROM
IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-3 signaling pathway activates the JAK/STAT, MAPK and PI 3-kinase signaling modules. There are today 184 companies plus partners developing 261 IL-3 pathway targeting drugs in 971 developmental...

July 2014
FROM
Lung Cancer Drug Pathway Analyzer 2014 Lung Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Lung Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 487 targeted molecular therapies known to affect more than 254 specific intracellular signaling pathways...

July 2014
FROM
Nucleic Acid Therapies in Oncology: Drug Pathway Analyzer 2014 Nucleic Acid Therapies in Oncology: Drug Pathway Analyzer 2014 - Product Thumbnail Image

Nucleic Acid Therapies in Oncology: Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 285 nucleic acid drugs known to affect more than 223 specific intracellular signaling pathways for the...

July 2014
FROM
Ovarian Cancer Drug Pipeline Update 2014 Ovarian Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Ovarian Cancer Drug Pipeline Update 2014

With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication for...

July 2014
FROM
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-5 singaling pathway activates the JAK/STAT and Raf/MAPK signaling modules. There are today 124 companies plus partners developing 167 IL-5 pathway targeting drugs in 667 developmental projects...

July 2014
FROM
Loading Indicator

Our Clients

Our clients' logos